RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Antibe Therapeutics Stock

Antibe Therapeutics Equity 2024

Antibe Therapeutics Equity

40.17 M CAD

Ticker

ATE.TO

ISIN

CA0370255097

WKN

A2QJPN

In 2024, Antibe Therapeutics's equity was 40.17 M CAD, a -29.32% increase from the 56.83 M CAD equity in the previous year.

Antibe Therapeutics Aktienanalyse

What does Antibe Therapeutics do?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Antibe Therapeutics's Equity

Antibe Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Antibe Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Antibe Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Antibe Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Antibe Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Antibe Therapeutics stock

What is the equity of Antibe Therapeutics this year?

Antibe Therapeutics has equity of 40.17 M CAD this year.

What was the equity of Antibe Therapeutics compared to the previous year?

The equity of Antibe Therapeutics has increased/decreased by -29.32% decreased compared to the previous year.

What impact does a high equity have on investors of Antibe Therapeutics?

A high equity is advantageous for investors of Antibe Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Antibe Therapeutics?

A low equity can be a risk for investors of Antibe Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Antibe Therapeutics affect the company?

An increase in equity of Antibe Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Antibe Therapeutics affect the company?

A reduction in equity of Antibe Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Antibe Therapeutics?

Some factors that can affect the equity of Antibe Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Antibe Therapeutics so important for investors?

The equity of Antibe Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Antibe Therapeutics take to change the equity?

To change equity, Antibe Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Antibe Therapeutics pay?

Over the past 12 months, Antibe Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antibe Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Antibe Therapeutics?

The current dividend yield of Antibe Therapeutics is .

When does Antibe Therapeutics pay dividends?

Antibe Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antibe Therapeutics?

Antibe Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Antibe Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antibe Therapeutics located?

Antibe Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antibe Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antibe Therapeutics from 9/30/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Antibe Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Antibe Therapeutics in the year 2023?

In the year 2023, Antibe Therapeutics distributed 0 CAD as dividends.

In which currency does Antibe Therapeutics pay out the dividend?

The dividends of Antibe Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Antibe Therapeutics

Our stock analysis for Antibe Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antibe Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.